• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

LEFTY2 Recombinant Monoclonal Antibody

The recombinant antibody against LEFTY2 was produced using a synthesized peptide derived from human LEFTY2 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB.

ADC-56667A

The recombinant antibody against LEFTY2 was produced using a synthesized peptide derived from human LEFTY2 as the immunogen. This antibody exists as a non-conjugated isotype Rabbit IgG, Affinity-chromatography purified. This antibody has been validated on ELISA, WB.

$350.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-56667A ClonalityMonoclonal
Target NameLEFTY2Target SynonymsEBAF LEFTA LEFTYA TGFB4, Left-right determination factor 2 (Endometrial bleeding-associated factor) (Left-right determination factor A) (Protein lefty-2) (Protein lefty-A) (Transforming growth factor beta-4) (TGF-beta-4), LEFTY2
FormLiquidSpecies ReactivityHuman
IsotypeRabbit IgGStorage BufferPH 7.4, 0.02% sodium azide and 50% glycerol., 150mM NaCl, Rabbit IgG in phosphate buffered saline
Purification MethodAffinity-chromatography purifiedConjugateNon-conjugated
ApplicationELISA, WBStorageUpon receipt

Immunogen Information


Immunogen DescriptionA synthesized peptide derived from human LEFTY2Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDO00292
Background Information
  • Uniprot Id

    O00292

  • Target Species

    Human

  • Target Name

    LEFTY2

  • Target Full Name

    Left-right determination factor 2

  • Target Function

    Required for left-right (L-R) asymmetry determination of organ systems in mammals. May play a role in endometrial bleeding.

  • Target Involvement

    Left-right axis malformations (LRAM)

  • Target Subcellular Location

    Secreted.

  • Target Protein Families

    TGF-beta family

  • Target Tissue Specificity

    Mesenchymal cells of the endometrial stroma.

  • Target Research Area

    Cancer

  • Target Synonyms

    EBAF; Endometrial bleeding associated factor (left right determination factor A transforming growth factor beta superfamily); Endometrial bleeding associated factor; Endometrial bleeding-associated factor; Left right determination factor 2; Left right determination factor A; Left-right determination factor 2; Left-right determination factor A; LEFTA; LEFTY 2; LEFTY2; LEFTYA; LFTY2 transforming growth factor; beta -4; LFTY2; mouse; homolog of; LFTY2_HUMAN; MGC46222; Protein lefty 2; Protein lefty A; Protein lefty-2; Protein lefty-A; Protein lefty2; PSEC0024; TGF beta 4; TGF-beta-4; TGFB4; Transforming growth factor beta 4; Transforming growth factor beta-4

  • Target Background

    This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate the mature protein, which plays a role in left-right asymmetry determination of organ systems during development. The protein may also play a role in endometrial bleeding. Mutations in this gene have been associated with left-right axis malformations, particularly in the heart and lungs. Some types of infertility have been associated with dysregulated expression of this gene in the endometrium. This gene is closely linked to both a related family member and a related pseudogene. This gene encodes multiple isoforms that may undergo similar proteolytic processing.

Inquire LEFTY2 Recombinant Monoclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification